Multiple Myeloma Specialist

Hear directly from experts who specialize in multiple myeloma.

Multiple myeloma is a cancer that starts in a type of white blood cell called plasma cells. While it is not curable, it is very treatable with a lot of research and clinical trials focused on trying to extend life on the path to a cure.

Explore interviews with medical experts who specialize in multiple myeloma, including oncologists who talk about latest in treatment trends amid a rapidly-shifting landscape that seems to favor new combinations. Also learn more about CAR T cell therapy and bispecifics in multiple myeloma.

Oncologists

Research on Black Myeloma Patients, Access & Disparities

Patient advocate Valarie Traynham and Dr. Shakira Grant discuss the barriers many Black patients face, how it impacts their care, and what can be done to help improve their outcomes.

Irene Ghobrial, MD

Role: Clinical investigator and professor of hematological oncology
Focus: Multiple myeloma, Waldenström’s Macroglobulinemia, early screening, clinical trials
Provider:Dana-Farber Cancer Institute (Boston)

James Berenson, MD

Oncologist: Specializing in myeloma and other blood and bone disorders
Experience: 35+ years
Institution: Berenson Cancer Center

Joseph Mikhael, MD

Role: Dir. Myeloma Research, CMO at International Myeloma Foundation (IMF)
Focus: Multiple myeloma
Provider: TGen/City of Hope

Nina Shah, MD

Role: Hematologist-oncologist, researcher
Focus: Multiple Myeloma
Institution: University of California, San Francisco (UCSF)

Rafael Fonseca, MD

Role: Interim executive director, hematologist-oncologist
Focus: Multiple myeloma, new drug development
Institution: Mayo Clinic

Vincent Rajkumar, MD

Dr. Vincent Rajkumar, a hematologist oncologist at the Mayo Clinic, talks about drug pricing and the impact of high prescription drug costs on patients and families.

High-Risk Smoldering Multiple Myeloma Highlights from ASH 2022

Patient advocate Jack Aiello and hematologist Dr. Shaji Kumar discuss what high-risk smoldering patients can do to delay or possibly avoid progression to active myeloma.

Multiple Myeloma in 2023

Long-time myeloma patient and advocate, Jack Aiello, leads the conversation with Dr. Joshua Richter, Multiple Myeloma Director for Blavatnik Family Chelsea Medical Center at Mount Sinai and Dr. Muhamed Baljević, Plasma Cell Disorders Research Director for Vanderbilt-Ingram Cancer Center.

Newly Diagnosed Multiple Myeloma Highlights from ASH 2022

Dr. Caitlin Costello and Dr. Sagar Lonial discuss treatments for newly diagnosed multiple myeloma patients.

Saad Z. Usmani, MD

Dr. Saad Usmani, Chief of Myeloma Service at Memorial Sloan Kettering, talks about CAR T-cell therapy, bispecific antibodies, novel therapies and combination therapies.

Relapsed/Refractory Multiple Myeloma Highlights from ASH 2022

Multiple myeloma specialists Dr. Ajai Chari with Mount Sinai in New York and Dr. Sandy Wong with the University of California San Francisco discuss the big buzz at this year’s ASH: bispecific antibodies.

The Doctor Talk w/ Dr. Gasparetto & Dr. Richter

Role: Dr. Cristina Gasparetto (Duke) and Dr. Joshua Richter Mount Sinai discuss latest relapsed refractory multiple myeloma treatments

The Latest in Multiple Myeloma Treatments: What Clinical Trials are Available to Me?

Patient advocate Cindy Chmielewski, experts Dr. Carl Ola Landgren and Dr. Caitlin Costello, together with clinical trial nurse Christen Hawthorne uncover groundbreaking insights on the latest multiple myeloma treatments and clinical trials.

The Latest in Multiple Myeloma: Understanding Promising Treatment Options

Patient advocates Cindy Chmielewski and Jack Aiello, and experts Dr. Rafael Fonseca and Dr. Susan Bal discuss promising multiple myeloma treatment options.

The Role of Bispecific Antibodies in the Treatment of Multiple Myeloma

Hematologist Alfred Garfall, MD, MS, from Penn Medicine discusses with multiple myeloma patient advocate Jack Aiello the advancement of immunotherapy for multiple myeloma, the difference between CAR T-cell therapy & bispecific antibodies, and the role of bispecifics in the myeloma toolkit of immunotherapies.

Multiple Myeloma Specialist

Hear directly from experts who specialize in multiple myeloma.

Oncologists

Join Our Community